NASDAQ:PRTK

Paratek Pharmaceuticals Competitors

$7.96
+1.01 (+14.53 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.94
Now: $7.96
$8.46
50-Day Range
$6.84
MA: $7.40
$8.16
52-Week Range
$3.81
Now: $7.96
$8.75
Volume5.23 million shs
Average Volume466,597 shs
Market Capitalization$373.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

Paratek Pharmaceuticals (NASDAQ:PRTK) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying PRTK stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Paratek Pharmaceuticals, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Paratek Pharmaceuticals (NASDAQ:PRTK) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Johnson & Johnson's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03
Johnson & Johnson$82.06 billion5.17$15.12 billion$8.6818.58

Johnson & Johnson has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Paratek Pharmaceuticals00303.00
Johnson & Johnson031102.79

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Johnson & Johnson has a consensus price target of $180.6429, indicating a potential upside of 12.03%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Johnson & Johnson.

Profitability

This table compares Paratek Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Paratek Pharmaceuticals-248.03%N/A-43.44%
Johnson & Johnson21.01%34.64%13.40%

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Paratek Pharmaceuticals (NASDAQ:PRTK) and Pfizer (NYSE:PFE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Pfizer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03
Pfizer$51.75 billion3.94$16.27 billion$2.9512.41

Pfizer has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Paratek Pharmaceuticals00303.00
Pfizer010302.23

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Pfizer has a consensus price target of $38.5714, indicating a potential upside of 5.39%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Pfizer.

Profitability

This table compares Paratek Pharmaceuticals and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Paratek Pharmaceuticals-248.03%N/A-43.44%
Pfizer17.85%24.88%9.32%

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Pfizer beats Paratek Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Paratek Pharmaceuticals (NASDAQ:PRTK) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares Paratek Pharmaceuticals and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Paratek Pharmaceuticals-248.03%N/A-43.44%
Merck & Co., Inc.24.33%53.83%16.83%

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Paratek Pharmaceuticals00303.00
Merck & Co., Inc.021202.86

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Merck & Co., Inc. has a consensus price target of $95.9167, indicating a potential upside of 25.69%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Merck & Co., Inc..

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Merck & Co., Inc.'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.70

Merck & Co., Inc. has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares AbbVie and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Paratek Pharmaceuticals-248.03%N/A-43.44%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AbbVie and Paratek Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121402.76
Paratek Pharmaceuticals00303.00

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 7.63%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than AbbVie.

Institutional & Insider Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares AbbVie and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.71$7.88 billion$8.9412.03
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03

AbbVie has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Eli Lilly and and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Paratek Pharmaceuticals-248.03%N/A-43.44%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Paratek Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
Paratek Pharmaceuticals00303.00

Eli Lilly and currently has a consensus target price of $196.40, indicating a potential upside of 6.46%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than Eli Lilly and.

Institutional & Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Eli Lilly and has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Eli Lilly and and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion7.93$8.32 billion$6.0430.54
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03

Eli Lilly and has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Bristol-Myers Squibb and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Paratek Pharmaceuticals-248.03%N/A-43.44%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bristol-Myers Squibb and Paratek Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Paratek Pharmaceuticals00303.00

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 19.22%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than Bristol-Myers Squibb.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bristol-Myers Squibb and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.35$3.44 billion$4.6913.35
Paratek Pharmaceuticals$16.54 million22.57$-128,790,000.00($3.93)-2.03

Bristol-Myers Squibb has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Paratek Pharmaceuticals on 9 of the 15 factors compared between the two stocks.


Paratek Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.25+1.1%$424.52 billion$82.06 billion25.35
Pfizer logo
PFE
Pfizer
2.3$36.60+1.7%$204.14 billion$51.75 billion23.61Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.31+1.1%$193.09 billion$46.84 billion16.88News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.54+1.3%$189.79 billion$33.27 billion22.74Analyst Report
Eli Lilly and logo
LLY
Eli Lilly and
2.1$184.49+1.0%$176.92 billion$22.32 billion30.15
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.61+1.1%$139.87 billion$26.15 billion-569.13Analyst Upgrade
Zoetis logo
ZTS
Zoetis
2.2$159.85+0.1%$75.93 billion$6.26 billion47.43
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.31+0.9%$25.69 billionN/A0.00Analyst Revision
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.48+0.5%$20.50 billion$1.30 billion24.99Analyst Upgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40+0.3%$9.09 billion$2.16 billion50.91Insider Selling
Perrigo logo
PRGO
Perrigo
2.5$40.53+0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63+3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31+0.7%$1.50 billion$392.76 million11.75Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.20+1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Omeros logo
OMER
Omeros
1.4$18.23+2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.27+0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.55+2.8%$358.06 million$111.39 million25.36News Coverage
Gap Down
Lannett logo
LCI
Lannett
2.0$4.95+1.6%$204.94 million$545.74 million-6.87Analyst Upgrade
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.36+0.5%$166.75 million$15.96 million-2.64Unusual Options Activity
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17+4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.